Sionna Therapeutics is implementing significant layoffs, reducing its workforce by approximately 46%. This decision follows the failure of its SION-719 cystic fibrosis trial. The company is shifting its focus to a new dual combination therapy. This strategic pivot aims to advance a different NBD1 stabilizer and CFTR corrector. The restructuring is expected to extend the company's cash runway.
Boston, MA
https://www.fiercebiotech.com/biotech/sionna-lays-46-workforce-strategic-shift-after-cystic-fibrosis-trial-fail